Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the browsers below.

Internet Explorer 10, Firefox, Chrome, or Safari.

Skip To Content
Volunteer Advocate

Clinical Trials Network

Clinical trials test potential new drugs, treatments and devices to assess how well they work, and whether they offer benefits over currently used drugs, treatments or therapies. Drugs and devices are first tested in research laboratories where experiments are done on animals and human cells. If the research is successful and the drug or treatment is deemed safe, it will go into the first phase of a clinical trial. View the Clinical Trial Road Map to see what happens throughout the different phases of a clinical trial.


CYSTIC FIBROSIS CANADA ACCELERATING CLINICAL TRIALS NETWORK (CF CanACT)

In keeping with its vision of a world without cystic fibrosis, Cystic Fibrosis Canada has established a Canadian clinical trials network, Cystic Fibrosis Canada Accelerating Clinical Trials (CF CanACT). World-class clinical trials are an integral part of the process that brings new therapeutics and better care to Canadians who are living with cystic fibrosis. The establishment of CF CanACT will help to facilitate the development of these new treatments for cystic fibrosis, as well as increase capacity and enhance participation of people with cystic fibrosis in clinical trials.

The CF CanACT network presently consists of six sites across Canada (one in Montréal, two in Toronto, one in Calgary and two in Vancouver). Gradually, the network will expand to include more sites. In the meantime, anyone with cystic fibrosis living in Canada is eligible to be referred to one of these sites to participate in a clinical trial, and can participate if they meet the inclusion criteria of the specific trial.

The investigators and research coordinators from the six sites, along with an adult patient representative and a CF parent, collaborate to review research protocols, standardize outcome measures between sites, and ensure that the clinical trial is feasible to perform and relevant to their patients.Have questions about clinical trials or CF CanACT? Contact clinicaltrials@cysticfibrosis.ca

Want to learn more about clinical trials? Check out Cystic Fibrosis Canada’s Clinical Trial information Kit for everything you need to know to make an informed decision about whether you CanACT and participate in clinical trials in Canada.

Downloadable PDF

Clinical Trial Finder

View the list of cystic fibrosis related clinical trials in Canada below:

Type of Study: CFTR function study. Examining the safety, tolerability, and how the body processes the drug in multiple ascending doses of PTI-808 and PTI-808 together with PTI-428 and PTI-801.
Clinical Trials.gov: https://clinicaltrials.gov/show/nct03251092                 
Duration: 56 days
Status: Enrolling
Population: Participants must have at least one copy of F508del mutation. In addition, they must not have taken a CFTR modulator for 14 days prior to screening.
Treatment: PTI-808 + PTI-801/ PTI-808 + PTI-428/ placebo
Age: 18+ years
Sites and Contacts:

Montreal Children's Hospital, Montreal - Navneethan Veluppillai navneethan.veluppillai@muhc.mcgill.ca

St. Michael's Hospital, Toronto - Katie Griffin griffink@smh.ca

St. Paul's Hospital, Vancouver - Eri Flores eflores@providencehealth.bc.ca    

Type of Study: Mucolytic (BI)
Clinical Trials.gov: Not registered yet 
Duration: 4 weeks 
Status: Not yet enrolling 
Population: Confirmed diagnosis of CF, stable with an FEV1 between 40% and 90% predicted
Treatment: Twice daily administration of BI1265162 by a Respimat inhaler
Age: 12+
Sites and Contacts:

B.C. Children's Hospital, Vancouver - Alam Lakhani  alam.lakhani@cw.bc.ca     

Montreal Chest Institute, Montreal - Navneethan Veluppillai navneethan.veluppillai@muhc.mcgill.ca

SickKids Hospital, Toronto - Stephanie Janneret Manning - Stephanie.jeanneretmanning@sickkids.ca   

St. Michael's Hospital, Toronto - Katie Griffin griffink@smh.ca

St. Paul's Hospital, Vancouver - Eri Flores eflores@providencehealth.bc.ca    

 

Type of Study: Anti-inflammatory study. Examines the effectiveness and safety of an anti-inflammatory drug against placebo.
Clinical Trials.gov: https://clinicaltrials.gov/ct2/show/NCT03265288         
Duration: 26 weeks
Status: Enrolling
Population: CF who have used at least 1 IV antibiotics for the treatment of a respiratory exacerbation within 12 months. FEV1 40 - 100% 
Age: 18+ years
Sites and Contacts: 

Centre hospitalier de l'Universite de Montreal (CHUM), Montreal - Navneethan Veluppillai navneethan.veluppillai@muhc.mcgill.ca

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec - Nathalie Vadeboncoeur nathalie.vadeboncoeur@criucpq.ula

McGill University Health Centre, Montreal - Navneethan Veluppillai navneethan.veluppillai@muhc.mcgill.ca

The Ottawa Hospital, Ottawa - Shawn Aaron saaron@ohri.ca

 

Type of Study: Modulator 
Clinical Trials.gov: https://clinicaltrials.gov/ct2/show/NCT03969888                
Duration: 29 Days
Status: Not yet enrolling
Population: Participants must have two copies of F508del mutation. In addition, they must not have taken a CFTR modulator for at least 60 days prior to screening. FEV1 40% to 90%.
Age: 18+ years
Sites and Contacts:

B.C. Children's Hospital, Vancouver - Alam Lakhani alam.lakhani@cw.bc.ca      

Montreal Chest Institute, Montreal - Navneethan Veluppillai navneethan.veluppillai@muhc.mcgill.ca

St. Michael's Hospital, Toronto - Katie Griffin griffink@smh.ca

St. Paul's Hospital, Vancouver - Eri Flores eflores@providencehealth.bc.ca     

 Foothills Medical Centre, Calgary - Clare Smith  Clare.Smith@albertahealthservices.ca

 

Type of Study: Anti-infective study. To evaluate the effectiveness of the inhaled nitric oxide in adults who are taking an inhaled antibiotic.
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT02498535  
Duration: 36 days
Status: Enrolling
Population: To participate, adults with CF must have taken an inhaled antibiotic for at least three months prior to the beginning of the study (for cycled antibiotics, participants must have completed two cycles). This study is for people who are chronically infected with Pseudomonas aeruginosa or Staphlococcus aureus, or Stenotrophomonas maltophilia.
Treatment: inhaled NO/placebo.
Age: 18+ years
Sites and Contacts: St. Paul's Hospital, Vancouver - Eri Flores eflores@providencehealth.bc.ca     

Type of Study: Anti-inflammatory study. Examines the safety and effectiveness of an anti-inflammatory drug against a placebo drug.
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT03451045 
Duration: 32 weeks
Status: Enrolling
Population: This study is for adults with cystic fibrosis who have been treated with antibiotics for a new exacerbation two or three times in the last year, including at least one treatment with IV antibiotics. This study may require lung function tests and/or other measurements.
Treatment: Lenabasum
Age: 12+ years
Sites and Contacts:

SickKids Hospital, Toronto - Stephanie Janneret Manning - Stephanie.jeanneretmanning@sickkids.ca

St. Michael's Hospital, Toronto - Katie Griffin griffink@smh.ca

St. Paul's Hospital, Vancouver - Eri Flores eflores@providencehealth.bc.ca     

 

Type of Study: Investigator initiated trial on antibiotic use
Clinical Trials.gov: Not yet registered              
Duration: 3 weeks active treatment
Status: Enrolling
Population: CF culture positive for Staphylococcus aureus
Treatment: Cephalexin or placebo
Age: 3 - 16 years
Sites and Contacts:

B.C. Children's Hospital, Vancouver - Alam Lakhani  alam.lakhani@cw.bc.ca     

SickKids Hospital, Toronto - Stephanie Janneret Manning - Stephanie.jeanneretmanning@sickkids.ca

 

Type of Study: Modulator
Clinical Trials.gov: https://clinicaltrials.gov/show/nct04043806                 
Duration: 100 weeks
Status: Only open to participants of VX 659-105
Population: CF homozygous or heterozygous for F508del and a minimally function mutation
Treatment: VX-661/VX-770 elexecaftor
Age: 12+ years
Sites and Contacts: St. Michael's Hospital, Toronto - Katie Griffin griffink@smh.ca

Type of Study: Modulator
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT03691779 
Duration:  32 weeks
Status: Enrolling
Population: CF homozygous or heterozygous for F508del and a minimally function mutation, FEV1 40% to 100%
Treatment: All participants will receive the triple combination drug VX-659 with ivacaftor and tezacaftor
Age:  6-11 years
Sites and Contacts:

B.C. Children's Hospital, Vancouver - Alam Lakhani  alam.lakhani@cw.bc.ca      

SickKids Hospital, Toronto - Stephanie Janneret Manning - Stephanie.jeanneretmanning@sickkids.ca

Type of Study: CFTR function study, evaluating the long-term effectiveness, safety, and effect on the body of the drug VX-445 in combination with tezacaftor and ivacaftor. 
Clinical Trial.gov : https://clinicaltrials.gov/ct2/show/NCT03525574        
Duration: 96 weeks
Status:  Enrollment complete
Population:  CF Heterozygous F508del  & a Minimal Function Mutation (F/MF)
Treatment: VX-445, tezacaftor, and ivacaftor or placebo
Age:12+ years
Sites and Contacts:

B.C. Children's Hospital, Vancouver - Alam Lakhani  alam.lakhani@cw.bc.ca      

Foothills Medical Centre, Calgary - Clare Smith Clare.Smith@albertahealthservices.ca

Montreal Children's Hospital, Montreal - Navneethan Veluppillai  navneethan.veluppillai@muhc.mcgill.ca

SickKids Hospital,Toronto - Stephanie Janneret Manning   Stephanie.jeanneretmanning@sickkids.ca

St. Paul's Hospital, Vancouver - Eri Flores eflores@providencehealth.bc.ca     

 

Type of Study: CFTR function study, evaluating the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects aged 6 - 11 years.
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT03537651 
Duration: 96 Weeks
Status: Closed to enrollment
Population: CF Homozygous or Heterozygous F508del
Treatment: VX-661 (tezacaftor)/Ivacaftor
Age: 6+ years
Sites and Contacts:

B.C. Children's Hospital, Vancouver - Alam Lakhani alam.lakhani@cw.bc.ca          

Montreal Children's Hospital, Montreal - Navneethan Veluppillai navneethan.veluppillai@muhc.mcgill.ca

SickKids Hospital, Toronto - Stephanie Janneret Manning   Stephanie.jeanneretmanning@sickkids.ca

 

Type of Study: CFTR function study looking at the safety of ivacaftor (Kalydeco) in babies with CF, measuring the amount of the drug in the bloodstream.
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT02725567 
Duration: 24 weeks
Status: Enrolling 
Population: CF with a gating mutation
Treatment: Ivacator. Requires blood tests, eye exams, sweat tests, and ECGs
Age: 0-24 months
Sites and Contacts: SickKids Hospital, Toronto - Stephanie Janneret Manning Stephanie.jeanneretmanning@sickkids.ca

Type of Study: CFTR function study Evaluaing the safety and effectiveness of long-term ivacaftor in babies who have a CFTR gating mutation.
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT03277196 
Duration: 96 weeks
Status: Enrollment Complete
Population: CF with a gating mutation
Treatment: Ivacator
Age: 0-24 months
Sites and Contacts: SickKids Hospital, Toronto - Stephanie Janneret Manning Stephanie.jeanneretmanning@sickkids.ca

Type of Study: CFTR function study, examining the safety and tolerability of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT03601637  
Duration: 24 weeks
Status:  Enrolling
Population: CF Homozygous F508del-CFTR Mutation
Treatment: Lumacaftor/Ivacaftor. This is an open label study meaning that all participants will receive Lumacaftor/Ivacaftor.
Age: 12-24 months
Sites and Contacts:

B.C. Children's Hospital, Vancouver - Alam Lakhani alam.lakhani@cw.bc.ca           

Montreal Children's Hospital, Montreal - Navneethan Veluppillai navneethan.veluppillai@muhc.mcgill.ca

SickKids Hospital, Toronto - Stephanie Janneret Manning Stephanie.jeanneretmanning@sickkids.ca  

 

Type of Study: CFTR function Study evaluating the long term safety and efficacy of VX-659 Combination Therapy
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT03447262 
Duration: 96 weeks
Status: Not open to enroll
Population: CF Heterozygous F508del and a Minimal Function Mutation (F/MF)
Treatment: tezacaftor/ivacaftor/659
Age: 12+ years
Sites and Contacts: St. Michael's Hospital, Toronto - Katie Griffin griffink@smh.ca

Type of Study: Anti-infective study. Examines the effectiveness of the inhaled drug vancomycin in adults and children with positive cultures for methicillin-resistant Staphylococcus aureus (MRSA).
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT03181932  
Duration: 48 weeks
Status: Enrolling
Population: CF with chronic MRSA FEV1 30 - 90%
Treatment: AeroVanc (inhaled Vancomycin) or placebo
Age: 6+ years
Sites and Contacts:

B.C. Children's Hospital, Vancouver - Alam Lakhani alam.lakhani@cw.bc.ca           

SickKids Hospital, Toronto - Stephanie Janneret Manning Stephanie.jeanneretmanning@sickkids.ca

Type of Study: Mucociliary clearance study. Assess whether inhalation of 7% hypertonic saline (HS) reduces structural lung disease as assessed by CT scan in preschool children
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT02950883
Duration: 1 year
Status: Enrolling
Population: CF between the ages of 3 - 6 years
Treatment: 7% hypertonic saline (HS) comparison with inhalation of 0.9% isotonic saline (IS)
Age: 3-6 years
Sites and Contacts:

B.C. Children's Hospital, Vancouver - Alam Lakhani alam.lakhani@cw.bc.ca    

SickKids Hospital, Toronto - Stephanie Janneret Manning Stephanie.jeanneretmanning@sickkids.ca

  

Type of Study: Anti-infective study. Examines the safety and effectiveness of different lengths of IV treatment for pulmonary exacerbations in people with CF.
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT02781610 
Duration: 35 days
Status: Enrolling
Population: CF with an acute respiratory exacerbation. This study will look at the safety and effectiveness of three different lengths of IV antibiotic treatment for pulmonary exacerbations.
Treatment: Participants who respond early to IV treatment will receive antibiotics for 10 or 14 days. Those who do not respond early will receive antibiotics for 14 or 21 days.
Age: 18+ years
Sites and Contacts:  Foothills Medical Centre, Calgary - Clare Smith Clare.Smith@albertahealthservices.ca

Type of Study: Anti-infective study. To evaluate the effectiveness of prednisone as an adjunctive treatment for patients who do not respond to regular IV antiiobitics
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT03070522 
Duration: 3 years
Status: Enrolling
Population: CF admitted with an acute respiratory exacerbation
Treatment: Prednisone or placebo
Age: 6+ years
Sites and Contacts:

B.C. Children's Hospital, Vancouver - Alam Lakhani alam.lakhani@cw.bc.ca   

Foothills Medical Centre, Calgary - Clare Smith Clare.Smith@albertahealthservices.ca  

SickKids Hospital, Toronto - Stephanie Janneret Manning Stephanie.jeanneretmanning@sickkids.ca

St. Michael's Hospital, Toronto - Katie Griffin griffink@smh.ca  

St. Paul's Hospital, Vancouver - Eri Flores eflores@providencehealth.bc.ca     

 

 

Type of Study: CFTR function study. Examines the safety and tolerability of the inhaled drug QR-010 which is a single-stranded RNA antisense oligonucleotide
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT02532764  
Duration: 8 weeks
Status: Complete
Population: CF homozygous F508del. FEV1 70% or greater
Treatment: PQ 010 or placebo
Age: 18+ years
Sites and Contacts: Foothills Medical Centre, Calgary - Clare Smith  Clare.Smith@albertahealthservices.ca

Type of Study: CFTR function study. Examining the safety and tolerability of the drug PTI-801
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT03140527
Duration: 30 days
Status: Complete
Population: CF subjects homozygous for the F508del-CFTR mutation. FEV1 40-90%
Treatment: PTI-801 + lumacaftor + ivacaftor/ PTI-801 + PTI-808/ placebo
Age: 18+ years
Sites and Contacts: St. Paul's Hospital, Vancouver - Eri Flores eflores@providencehealth.bc.ca

Type of Study: Muco-clearance study. An Efficacy and Safety Study on the use of SPX 101 which targets sodium channels
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT03229252 
Duration: 4 weeks
Status: Complete 
Population: CF with FEV1 40% - 70%
Treatment: SPX 101 or placebo
Age: 12+ years
Sites and Contacts:

Foothills Medical Centre, Calgary - Clare Smith Clare.Smith@albertahealthservices.ca

St. Michael's Hospital, Toronto - Katie Griffin griffink@smh.ca 

Type of Study: CFTR Function study designed to evaluate the safety and efficacy of long term treatment of lumacaftor in combination with ivacaftor.
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT02544451 
Duration: 96 Weeks
Status: Complete
Population: CF Homozygous F508del-CFTR Mutation
Treatment: Lumacaftor/Ivacaftor
Age: 6+ years
Sites and Contacts:

B.C. Children's Hospital, Vancouver - Alam Lakhani alam.lakhani@cw.bc.ca           

St. Paul's Hospital, Vancouver - Eri Flores eflores@providencehealth.bc.ca     

Type of Study: CFTR function study, Examining the safety and tolerability of the drug tezacaftor (VX-661) in combination with ivacaftor.
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT02953314 
Duration: 24 Weeks
Status: Complete
Population: CF Homozygous or Heterozygous for the F508del-CFTR Mutation
Treatment: VX-661 /Ivacaftor
Age: 6-11 years
Sites and Contacts:

B.C. Children's Hospital, Vancouver - Alam Lakhani alam.lakhani@cw.bc.ca      

Montreal Children's Hospital, Montreal - Navneethan Veluppillai navneethan.veluppillai@muhc.mcgill.ca

SickKids Hospital, Toronto - Stephanie Janneret Manning Stephanie.jeanneretmanning@sickkids.ca   

 

Type of Study: CFTR function study, evaluating the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older.
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT02565914  
Duration: 96 weeks
Status: Complete
Population: CF Homozygous or Heterozygouss F508del-CFTR Mutation
Treatment: tezacaftor/ ivacaftor
Age: 12+ years
Sites and Contacts:

Montreal Children's Hospital, Montreal - Navneethan Veluppillai navneethan.veluppillai@muhc.mcgill.ca

St. Michael's Hospital, Toronto - Katie Griffin griffink@smh.ca

Type of Study: CFTR function study, evaluating the effectiveness, safety, and effect on the body of the drug VX-445 in combination with tezacaftor and ivacaftor.
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT03525444
Duration: 24 Weeks
Status: Complete
Population: CF Heterozygous F508del and a Minimal Function Mutation (F/MF)
Treatment: VX-445, tezacaftor, and ivacaftor or placebo
Age: 12+ years
Sites and Contacts:

B.C. Children's Hospital, Vancouver - Alam Lakhani alam.lakhani@cw.bc.ca           

Foothills Medical Centre, Calgary - Clare Smith Clare.Smith@albertahealthservices.ca

Montreal Children's Hospital, Montreal - Navneethan Veluppillai navneethan.veluppillai@muhc.mcgill.ca

SickKids Hospital, Toronto - Stephanie Janneret Manning Stephanie.jeanneretmanning@sickkids.ca

St. Paul's Hospital, Vancouver - Eri Flores eflores@providencehealth.bc.ca     

 

Type of Study: CFTR function study, examining the safety and effect on the body of the drug VX-659 in combination with tezacaftor and ivacaftor
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT03447249  
Duration: 24 weeks
Status: Complete
Population: CF Heterozygous F508del and a Minimal Function Mutation (F/MF). FEV1 40-90%
Treatment: tezacaftor/ivacaftor/659
Age: 12+ years
Sites and Contacts: St. Michael's Hospital, Toronto - Katie Griffin griffink@smh.ca 

Type of Study: CFTR function study, to evaluate the Safety of Long-term Treatment With Lumacaftor/Ivacaftor Combination in 2 - 5 year olds
Clinical Trials.gov: https://clinicaltrials.gov/show/NCT03125395 
Duration: 96 Weeks
Status: Complete 
Population: CF Homozygous F508del-CFTR Mutation
Treatment: Lumacaftor/Ivacaftor
Age: 2-5 years
Sites and Contacts:

B.C. Children's Hospital, Vancouver - Alam Lakhani alam.lakhani@cw.bc.ca          

Montreal Children's Hospital, Montreal - Navneethan Veluppillai navneethan.veluppillai@muhc.mcgill.ca

For a full list of clinical trials visit: www.clinicaltrials.gov. ClinicalTrials.gov provides patients, their families and the public easy and free access to information on clinical trials.

TESTIMONIALS

To find more patients testimonials, check out our Youtube channel here.